Understand the source comparison
Kisspeptin Safety Profile: Clinical Data Comparison
This table compares the kisspeptin safety profile across different clinical contexts, administration routes, and study populations documented in peer-reviewed literature. Healthy men (dose escalation) IV infusion 0.01–6.4 nmol/kg/hr Mild headache (20%), transi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares the kisspeptin safety profile across different clinical contexts, administration routes, and study populations documented in peer-reviewed literature.
- Healthy men (dose escalation)
- IV infusion
- 0.01–6.4 nmol/kg/hr
- Mild headache (20%), transient flushing (13%)
- None reported
- Excellent tolerability even at supraphysiological doses; no dose-limiting toxicity identified
- Women with hypothalamic amenorrhea
- Subcutaneous bolus
- 0.3–1.0 nmol/kg
- Injection site erythema (18%), mild nausea (7%)
- Comparable safety to healthy volunteers; adverse events resolve spontaneously within 2–4 hours
- Men with hypogonadotropic hypogonadism
- Subcutaneous bolus (repeated)
- 1.0 nmol/kg twice weekly × 8 weeks
- Injection site reactions (22%), headache (11%)
- No cumulative toxicity after repeated dosing; receptor desensitization limits downstream hormonal effects
- Healthy women (reproductive phase)
- IV bolus
- 0.24–6.4 nmol/kg
- Transient warmth sensation (15%), headache (9%)
- Rapid clearance (t½ ~30 min) minimizes prolonged exposure; no cardiovascular or metabolic changes detected
- Healthy volunteers (intranasal)
- Intranasal spray
- 1.6–9.6 nmol total dose
- No mucosal irritation reported
- Limited data; bioavailability variability complicates dose standardization; safety profile favorable in preliminary studies